- Home
- MDRR vs TPST Comparison
MDRR vs TPST Comparison
Compare MDRR & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | TPST |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDRR | TPST |
|---|---|---|
| Price | $11.73 | $2.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 2.9K | ★ 86.5K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,098,461.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.83 | N/A |
| 52 Week Low | $9.55 | $2.40 |
| 52 Week High | $14.52 | $12.48 |
Technical Indicators
Market Signals| Indicator | MDRR | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 32.73 |
| Support Level | $12.00 | $2.55 |
| Resistance Level | $12.20 | $3.00 |
| Average True Range (ATR) | 0.31 | 0.23 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 0.00 | 7.49 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.